Insilico Medicine

We’re on the cusp of a revolutionary moment in science and medicine—a moment that redefines what’s possible. That’s why we’ve dedicated so much effort to telling the story of AI-powered drug discovery: to inspire people, regardless of their location or stage in life, to join this incredible community of innovators. We present you a documentary of the First:end-to-end discovery of a novel drug using generative AI, where AI powered every step—starting from identifying a new target and designing a new molecule, through advancing into Phase 0, Phase I, and Phase II clinical trials. -And the First: drug discovered through groundbreaking aging research, representing a monumental leap toward healthier, longer lives. -And the First Potential: Longevity gerotherapeutic-a drug designed to address the underlying biology of aging-developed with artificial intelligence as the driving force behind its discovery. These extraordinary milestones highlight how AI and cutting-edge scientific research are coming together to accelerate innovation in human health span. From initial conception to human trials, this journey serves as a testament to the transformational power of interdisciplinary collaboration.

🔬In the ever-evolving world of drug discovery and biomedical research, AI-powered platforms like #DORA are revolutionizing how we approach scientific breakthroughs. Whether you're a researcher in academia, a university leader, a biotech entrepreneur, or a business executive, DORA has something for you. 💡 For Academia & Universities: - Accelerate research with advanced AI-driven target discovery. - Gain data-driven insights to validate hypotheses faster than ever. 🧬 For Biomedical Research: -Leverage specialized templates for biomedical research, integrating with top databases like #PubMed. 💼 For Business & Industry Leaders: - Stay ahead in the race by leveraging AI to identify first-in-class targets. 🚀 DORA is designed to empower researchers, universities, and businesses alike to push the boundaries of what’s possible in drug discovery. Ready to explore how DORA can transform your research and business? 🔗 Discover more here: https://lnkd.in/en_u_eyF #AIinPharma #DrugDiscovery #BiomedicalResearch #Academia #Universities #Biotech #ArtificialIntelligence #InsilicoMedicine

And now for the expert panel discussion for "Machine Learning and AI Methods for Aging and Dementia Care" Panelists: Alex Zhavoronkov of Insilico Medicine | Michael Hughes of Tufts University | Brian Anderson, MD of Coalition for Health AI (CHAI)

NEW 📽️ from Bio-IT World Boston: Allison Proffitt catches up with Insilico Medicine’s Alex Zhavoronkov after the morning keynote at #BioITExpo that explored #GenerativeAI, aging research and robotics as a platform for #DrugDiscovery and why if a drug is powerful enough to work in aging, it should in multiple diseases. Check out the Plenary Keynote coverage here 👉 https://lnkd.in/efXgm42R

Bio-IT World is not over yet! Join Petrina Kamya, PhD, Global Head of AI Platforms & VP at Insilico Medicine, as she takes the stage for an exciting panel discussion on: 🎙️ Unlocking AI Potential: Best Practices for Implementation and Management 📍 Omni Boston Hotel & Virtual 📅 Today, April 2, 2025, 2:35 pm Featured Speakers: 🔹 Nagaraja Srivatsan – Founder, Vidya Seva (Chair & Moderator) 🔹 Dimitris K. Agrafiotis, PhD – Director, Digital, Analytics, and AI, Arsenal Capital Partners 🔹 Julie Bryant – Chief Strategy Officer & Founder, Rancho BioSciences 🔹 Vinod Das (SK) – R&D Drug Innovation, AI Solutions, Bayer Pharmaceuticals 🔹 Petrina Kamya, Ph.D. – Global Head of AI Platforms & VP, Insilico Medicine; President, Insilico Medicine Canada Join us for a dynamic discussion to harness AI’s full potential in life sciences innovation. https://lnkd.in/ejYqE_d2 #BioITExpo #BioITWorld #AIImplementation #BostonConferences

2025 could be a pillar year for AI-driven lab robotics in pharma and biotech, and here is why 🤖👇 📑 If you missed it, this recent publication from one of our portfolio companies, Insilico Medicine, is worth a close read (link in the comments). It describes how their AI platform was used to discover a novel TNIK inhibitor (INS018_055), a drug candidate with senomorphic activity targeting cellular senescence and SASP. But the core story isn’t just about the discovery of a new aging-related drug candidate, what’s more important—and in my view, a real paradigm shift—is the infrastructure and workflow behind it. ⚙️ Insilico demonstrates a fully integrated AI–robotics loop for drug discovery: 👉 Multi-omic data generation (genome, transcriptome, methylome) 👉 AI-driven target discovery via their PandaOmics platform 👉 Automated compound screening, phenotypic profiling, and wet-lab validation 👉 Real-time feedback and reinforcement learning to refine the models 👉 All executed within a modular six-unit robotics facility, handling everything from cell culture and compound management to high-content imaging and next-gen sequencing This kind of closed-loop system effectively collapses what used to take years into weeks. It's scalable, reproducible, and designed for continuous learning—a foundational shift in how we approach drug development. These end-to-end AI-native infrastructures are still rare. Insilico is one of only a few companies operating at this level, but I believe this is the blueprint for the future of drug discovery. 🚀 Kudos to Alex Zhavoronkov, Alex Aliper and the entire Insilico team for building and executing on a vision that brings true vertical integration to AI-powered drug discovery! 🙏 Image credit: Insilico Medicine

Allison Proffitt catches up with Insilico Medicine’s Alex Zhavoronkov after the morning keynote at #BioITExpo that explored #GenerativeAI, aging research and robotics as a platform for #DrugDiscovery and why if a drug is powerful enough to work in aging, it should in multiple diseases. Follow our YouTube channel https://lnkd.in/gFTv2W9u to catch up form videos and interviews form the conference.

🚨 Happening Today at Bio-IT World! Join Petrina Kamya, Ph.D., Global Head of AI Platforms & VP at Insilico Medicine, as she takes the stage to discuss "Revolutionizing Drug Discovery with Generative AI" 🤖. This talk will explore how generative AI is transforming this paradigm through Insilico Medicine’s innovative machine learning platform, enabling novel target identification, small molecule design, and clinical trial prediction. 📍 Boston, MA | Generative AI Track | Omni Boston Hotel Seaport ⏰ 3:30 pm 🔗 For more information, visit: https://bit.ly/3XIbLz0 #BioITWorld #GenerativeAI #AIforDrugDiscovery #InsilicoMedicine #PrecisionMedicine #BIOITExpo

🚨 Happening This Morning at Bio-IT World! 🚨 💡 Join Michelle Chen, PhD, VP at Insilico Medicine, and an esteemed panel of biotech investment leaders for a dynamic discussion on Optimizing Investment Strategies in Biotech. 🔍 What’s next for biotech funding? How can AI-driven drug discovery attract top investors? 📍 Omni Hotel Boston at the Seaport 🕘 This Morning at 8:40am. Don’t Miss It! 🔗 Learn more: https://bit.ly/42gOt4I #BioITWorld #BiotechInvestments #AIforDrugDiscovery #InsilicoMedicine #VentureInnovation #PrecisionMedicine #BioITExpo